The cardiovascular disease market, which includes hypertension, dyslipidemia, and thrombotic events, is set to grow from $129.2 billion in 2015 to $146.4 billion by 2022, at a very modest compound annual growth rate of 1.8 per cent, according to GBI Research.
The company’s latest report states that this relative stagnation can be attributed to major product approvals coinciding with key patent expirations. Within cardiovascular disease there are a number of blockbuster products that have recently gone off-patent, and others are expected to in the coming years, many of which belong to significant players.
For example, the current market leader, AstraZeneca’s Crestor (rosuvastatin), generated around $7 billion in 2011, with revenues expected to drop sharply following the expiration of its patent on July 8, 2016. Total annual revenues are forecast to be around $1.3 billion in 2022.
Thomas Jarratt, Associate Analyst, GBI Research, explains, “Unlike AstraZeneca, some key players will experience revenue growth resulting from the introduction of new products to market. In particular, Sanofi’s Praluent (alirocumab) is expected to help mitigate losses associated with falling revenues of its key products Lovenox (enoxaparin) and Plavix (clopidogrel). Novartis’ heart failure drug Entresto was introduced to market in July 2015, and GBI Research expects its revenues to increase dramatically during the forecast period. Entresto is a combination drug which has shown efficacy shown in clinical trials. Coupled with a high cost, which amounts to over $4,500 annually per patient, the drug contributes to a very high revenue forecast of $5.7 billion by 2022.”
EP News Bureau